In support of this, the first selective TYK2 inhibitor, deucravacitinib, is for the treatment of plaque psoriasis, with ongoing clinical trials in psoriatic arthritis, SLE, Crohn's disease, and ulcerative colitis. Here, TYK2 is linked to psoriatic arthritis.